Pharmacology of apolipoprotein A-I

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Atherosclerosis Research

Background:

• High-density lipoprotein (HDL) and its primary protein, apolipoprotein A-I (apoA-I), are recognized for their antiatherogenic roles.
• Established mechanisms include reverse cholesterol transport, anti-inflammatory effects, and antithrombotic functions.
• The relative importance of these mechanisms varies with atherosclerosis stage and type.

Purpose of the Study:

• To review the established and emerging roles of HDL and apoA-I in preventing atherosclerosis.
• To highlight the pharmacological advancements and clinical investigations involving apoA-I.

Main Methods:

• Review of experimental data and clinical studies on HDL and apoA-I.
• Analysis of the multifaceted antiatherogenic mechanisms.

Main Results:

• Experimental evidence supports three key antiatherogenic mechanisms: reverse cholesterol transport, anti-inflammation, and antithrombosis.
• ApoA-I pharmacology has seen significant recent progress.
• Clinical trials involving apolipoprotein A-I phospholipid complexes have commenced.

Conclusions:

• HDL and apoA-I play a crucial, multi-mechanistic role in combating atherosclerosis.
• Ongoing research in apoA-I pharmacology and clinical trials holds promise for cardiovascular disease treatment.